celecoxib,ipilimumab,nivolumab
bms
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'niche', 'rectal']
dr. luis diaz' important comment: importance of early immunotherapy intervention &amp; response for msi rectal caner patients (100% in trial vs approx 50% for stage iv patients thinking of mss patients in niche study who had response. #asco22 #crcsm
volunteer #CRCSM librarian
#BRAF & #NRAS FB grps
Stage 4 CRC Support & Colon Cancer Stars
trials Stage 2/3 pts
https://t.co/48vU5493pH